These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
318 related articles for article (PubMed ID: 37148355)
41. Treatment-related changes in neuroendocrine tumors as assessed by textural features derived from Weber M; Kessler L; Schaarschmidt B; Fendler WP; Lahner H; Antoch G; Umutlu L; Herrmann K; Rischpler C BMC Cancer; 2020 Apr; 20(1):326. PubMed ID: 32299391 [TBL] [Abstract][Full Text] [Related]
42. Radiopharmaceuticals used for diagnosis and therapy of NETs. Papachristou M Hell J Nucl Med; 2023; 26 Suppl():19-20. PubMed ID: 37658556 [TBL] [Abstract][Full Text] [Related]
43. Discordance Between Histopathologic Grading and Dual-Tracer PET/CT Findings in Metastatic NETs and Outcome of Adnan A; Basu S J Nucl Med Technol; 2022 Sep; 50(3):248-255. PubMed ID: 34876476 [TBL] [Abstract][Full Text] [Related]
44. Evaluating diagnostic accuracy and determining optimal diagnostic thresholds of different approaches to [ Kim SH; Roytman M; Madera G; Magge RS; Liechty B; Ramakrishna R; Pannullo SC; Schwartz TH; Karakatsanis NA; Osborne JR; Lin E; Knisely JPS; Ivanidze J Sci Rep; 2022 Jun; 12(1):9256. PubMed ID: 35661809 [TBL] [Abstract][Full Text] [Related]
46. Relationship Between Absorbed Dose and Response in Neuroendocrine Tumors Treated with [ Warfvinge CF; Gustafsson J; Roth D; Tennvall J; Svensson J; Bernhardt P; Åkesson A; Wieslander E; Sundlöv A; Sjögreen Gleisner K J Nucl Med; 2024 Jul; 65(7):1070-1075. PubMed ID: 38724277 [TBL] [Abstract][Full Text] [Related]
47. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971 [TBL] [Abstract][Full Text] [Related]
48. Differentiated thyroid cancer: a new perspective with radiolabeled somatostatin analogues for imaging and treatment of patients. Versari A; Sollini M; Frasoldati A; Fraternali A; Filice A; Froio A; Asti M; Fioroni F; Cremonini N; Putzer D; Erba PA Thyroid; 2014 Apr; 24(4):715-26. PubMed ID: 24102584 [TBL] [Abstract][Full Text] [Related]
49. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE. Ilan E; Sandström M; Wassberg C; Sundin A; Garske-Román U; Eriksson B; Granberg D; Lubberink M J Nucl Med; 2015 Feb; 56(2):177-82. PubMed ID: 25593115 [TBL] [Abstract][Full Text] [Related]
50. 68 Ga-DOTATOC Pictorial Essay of Various Recurrent Meningiomas Rejected for Treatment With 177 Lu-DOTATATE : Is There a Place for Another Theranostic Examination? Moreau A; Maureille A; Kryza D Clin Nucl Med; 2024 Jul; 49(7):655-658. PubMed ID: 38689436 [TBL] [Abstract][Full Text] [Related]
51. 4D SPECT/CT acquisition for 3D dose calculation and dose planning in (177)Lu-peptide receptor radionuclide therapy: applications for clinical routine. Kairemo K; Kangasmäki A Recent Results Cancer Res; 2013; 194():537-50. PubMed ID: 22918781 [TBL] [Abstract][Full Text] [Related]
52. 177Lu-labeled somatostatin receptor targeted radionuclide therapy dosimetry in meningioma: a systematic review. Boursier C; Zaragori T; Imbert L; Verger A Q J Nucl Med Mol Imaging; 2024 Jul; ():. PubMed ID: 39026463 [TBL] [Abstract][Full Text] [Related]
53. Impact of 68Ga-DOTATOC PET/MRI on robotic radiosurgery treatment planning in meningioma patients: first experiences in a single institution. Acker G; Kluge A; Lukas M; Conti A; Pasemann D; Meinert F; Anh Nguyen PT; Jelgersma C; Loebel F; Budach V; Vajkoczy P; Furth C; Baur ADJ; Senger C Neurosurg Focus; 2019 Jun; 46(6):E9. PubMed ID: 31153151 [TBL] [Abstract][Full Text] [Related]